Table 2.
Crude and overlap propensity score weighted odds ratios of dates of statin prescription for gastric cancer according to statin type.
| Characteristics | Gastric Cancer | Control | Odds Ratios for Gastric Cancer (95% Confidence Interval) | |||
|---|---|---|---|---|---|---|
| % | % | Crude | p-Value | Overlap Weighted Model † | p-Value | |
| Any statin | ||||||
| <180 days | 87.7 | 86.8 | 1 | 1 | ||
| 180–545 days | 5.7 | 6.3 | 0.89 (0.80–0.98) | 0.021 * | 0.88 (0.81–0.86) | 0.002 * |
| >545 days | 6.6 | 6.9 | 0.94 (0.86–1.04) | 0.214 | 0.96 (0.89–1.04) | 0.292 |
| Hydrophilic statins | ||||||
| <180 days | 97.8 | 97.7 | 1 | 1 | ||
| 180–545 days | 1.1 | 1.3 | 0.85 (0.68–0.95) | 0.149 | 0.78 (0.66–0.92) | 0.004 * |
| >545 days | 1.1 | 1.0 | 1.11 (0.89–1.39) | 0.368 | 1.03 (0.86–1.23) | 0.733 |
| Lipophilic statins | ||||||
| <180 days | 89.7 | 88.8 | 1 | 1 | ||
| 180–545 days | 5.3 | 5.7 | 0.91 (0.82–1.01) | 0.074 | 0.91 (0.84–0.99) | 0.039 * |
| >545 days | 5.0 | 5.5 | 0.91 (0.82–1.01) | 0.085 | 0.96 (0.88–1.04) | 0.327 |
The total numbers of gastric cancer patients and controls were 8789 and 35,192, respectively. * Significance at p < 0.05. † Adjusted for age, sex, income, region of residence, systolic blood pressure, diastolic blood pressure, fasting blood glucose, total cholesterol, obesity, smoking, alcohol consumption, dyslipidemia history, and Charlson Comorbidity Index (CCI) scores.